期刊
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
卷 54, 期 2, 页码 129-134出版社
DUSTRI-VERLAG DR KARL FEISTLE
DOI: 10.5414/CP202296
关键词
hemocoagulase agkistrodon; adverse drug reaction; anaphylactic shock; literature review; dextran
资金
- Zhejiang Provincial Natural Science Foundation of China [LQ12H30001]
- Zhejiang Province funds for Health Department [2012RCB041]
- Zhejiang Medical Association Clinical Scientific Research Fund [2012ZYC-A109]
Hemocoagulase agkistrodon for injection is the national first-class new drug of China with good hemostatic function and safety for capillary hemorrhage in abdominal incision of surgical patients. Adverse drug reactions (ADRs) to hemocoagulase agkistrodon are rarely reported. In this paper, we describe a case of a 41-year-old woman who developed anaphylactic shock attributed to hemocoagulase agkistrodon before colon cancer surgery. Based on the Naranjo ADR probability score, a probable cause and effect relationship existed for this case. Although the cause of anaphylactic reaction (hemocoagulase or excipient) and exact mechanism of hemocoagulase agkistrodon-induced anaphylactic reaction are unknown, attention should be drawn to potential ADRs in clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据